دورية أكاديمية

ZBTB2 links p53 deficiency to HIF‐1‐mediated hypoxia signaling to promote cancer aggressiveness.

التفاصيل البيبلوغرافية
العنوان: ZBTB2 links p53 deficiency to HIF‐1‐mediated hypoxia signaling to promote cancer aggressiveness.
المؤلفون: Koyasu, Sho, Horita, Shoichiro, Saito, Keisuke, Kobayashi, Minoru, Ishikita, Hiroshi, Chow, Christalle CT, Kambe, Gouki, Nishikawa, Shigeto, Menju, Toshi, Morinibu, Akiyo, Okochi, Yasushi, Tabuchi, Yoshiaki, Onodera, Yasuhito, Takeda, Norihiko, Date, Hiroshi, Semenza, Gregg L, Hammond, Ester M, Harada, Hiroshi
المصدر: EMBO Reports; 1/9/2023, Vol. 24 Issue 1, p1-13, 13p
مستخلص: Aberrant activation of the hypoxia‐inducible transcription factor HIF‐1 and dysfunction of the tumor suppressor p53 have been reported to induce malignant phenotypes and therapy resistance of cancers. However, their mechanistic and functional relationship remains largely unknown. Here, we reveal a mechanism by which p53 deficiency triggers the activation of HIF‐1‐dependent hypoxia signaling and identify zinc finger and BTB domain‐containing protein 2 (ZBTB2) as an important mediator. ZBTB2 forms homodimers via its N‐terminus region and increases the transactivation activity of HIF‐1 only when functional p53 is absent. The ZBTB2 homodimer facilitates invasion, distant metastasis, and growth of p53‐deficient, but not p53‐proficient, cancers. The intratumoral expression levels of ZBTB2 are associated with poor prognosis in lung cancer patients. ZBTB2 N‐terminus‐mimetic polypeptides competitively inhibit ZBTB2 homodimerization and significantly suppress the ZBTB2–HIF‐1 axis, leading to antitumor effects. Our data reveal an important link between aberrant activation of hypoxia signaling and loss of a tumor suppressor and provide a rationale for targeting a key mediator, ZBTB2, to suppress cancer aggressiveness. Synopsis: Aberrant activation of HIF‐1 and p53 deficiency induce malignancy and therapy‐resistance. ZBTB2 links activation of hypoxia signaling and tumor suppressor dysfunction, thereby promoting cancer aggressiveness, thus representing a target to treat p53‐deficient cancers. ZBTB2 forms homodimers via its N‐terminus and increases the transactivation activity of HIF‐1 in p53‐deficient cells.ZBTB2 homodimers facilitate invasion, distant metastasis, and growth of p53‐deficient cancers.The intratumoral expression levels of ZBTB2 are associated with poor prognosis of lung cancer patients.Inhibition of ZBTB2 homodimerization suppresses the ZBTB2‐HIF‐1 axis, leading to antitumor effects. [ABSTRACT FROM AUTHOR]
Copyright of EMBO Reports is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:1469221X
DOI:10.15252/embr.202154042